EN DE
Watch Hainan Shuangcheng Pharmaceut for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Hainan Shuangcheng Pharmaceut (002693) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Hainan Shuangcheng Pharmaceut stock ¥0.71, price ¥6.95, that is 89.8% below the price, quality 66 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100001K63

HS Hainan Shuangcheng Pharmaceut logo Thin data Nov 21, 2026

Hainan Shuangcheng Pharmaceut

002693 · SHE

Far too expensive (fair value 90% below the price), but solid company and rising price: meets 2 of 3 rules.

Follow free in the weekly email
Quality 66/100 
Rising price (uptrend) 
Solidly profitable · 14.7% net margin (TTM) 
Low debt 
Generates free cash flow 
Moderate moat 48/100 · thin data
Revenue last quarter 12% below a year ago. 
Changed on Nov 21: ¥4.74 → ¥0.71 
Fair value ¥0.71 · Strongly overvalued 
Weak Growth (revenue 5y +0.5 %/yr in CNY) 
Trails peers (5/14) 
Thin data 
Extreme value
Watch Hainan Shuangcheng Pharmaceut for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥38.37 ¥3.75 Fair Value ¥0.71 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

60‑month range ¥3.75 – ¥38.37 · fair‑value band ¥0.44 – ¥1.03 · the ¥6.95 price screens above the ¥0.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 21, 2026.

Follow Hainan Shuangcheng Pharmaceut in your weekly email

Every Wednesday you see whether Hainan Shuangcheng Pharmaceut is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally.

Show moreShow less

The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism.

It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pregabalin capsule; and Memantine Hydrochloride tablets and Pioglitazone tablets USP. Hainan Shuangcheng Pharmaceuticals Co., Ltd. was founded in 2000 and is headquartered in Haikou, the People's Republic of China.

Stock analysis

Hainan Shuangcheng Pharmaceut (002693) currently trades at ¥6.95, while our model-based Fair Value estimate is ¥0.71, 90% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥0.895 per share, and 0 of the 26 models we run sit above the ¥6.95 price.

Bear case: the Dividend Discount group reads lowest at ¥0.155, and 26 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥0.44 (bear) to ¥1.03 (bull), the price of ¥6.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Hainan Shuangcheng Pharmaceut reported revenue of 277M CNY in FY2025 versus 320M CNY in FY2021, a compound −3.6%/yr. Reported net income was 19.0M CNY in FY2025.

Key figures

Market cap 2.9B CNY (≈ $432M) Small · P/E ratio 63.2 · P/S ratio 8.85 · EPS (TTM) ¥0.11 · Dividend yield 0.2% · Net margin 14.7% · Return on equity 8.1% · Return on assets (EBIT) −5.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −90%, 002693 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0200 to ¥2.42). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥0.44 Fair Value ¥0.71 Bull ¥1.03
Price ¥6.95 · Downside -89.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (¥0.0979 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ¥0.3500 ¥0.5200 ¥0.7400 79
Growth DCF ¥0.3600 ¥0.5100 ¥0.6900 78
Owner Earnings ¥0.4000 ¥0.5900 ¥0.8400 76
All 26 models by family
DCF Models
FCF DCF ¥0.3500 ¥0.5200 ¥0.7400 79
Owner Earnings ¥0.4000 ¥0.5900 ¥0.8400 76
5Y Revenue Exit ¥0.3100 ¥0.4900 ¥0.7100 71
5Y EBITDA Exit ¥0.7900 ¥1.37 ¥2.03 73
5Y P/E Exit ¥0.5100 ¥0.8600 ¥1.22 69
10Y Revenue Exit ¥0.3100 ¥0.4700 ¥0.6700 66
10Y EBITDA Exit ¥0.6100 ¥1.04 ¥1.60 66
10Y P/E Exit ¥0.4400 ¥0.7100 ¥1.03 63
Earnings-Based
Graham-Dodd ¥0.3100 ¥0.8600 ¥1.13 65
Lynch FV ¥0.2700 ¥0.3800 ¥0.5000 61
PEG = 1.0 ¥0.2700 ¥0.3800 ¥0.5000 57
EPV ¥0.2400 ¥0.2800 ¥0.3100 73
Dividend Discount
Gordon GGM ¥0.0900 ¥0.1700 ¥0.2400 67
DDM Multi-Stage ¥0.0900 ¥0.1400 ¥0.1800 67
Multiples
P/E Multiple ¥0.7600 ¥1.01 ¥1.26 63
P/S Multiple ¥0.5900 ¥0.7800 ¥0.9800 57
P/B Multiple ¥1.82 ¥2.42 ¥3.03 55
EV/EBIT ¥0.4400 ¥0.6000 ¥0.7600 65
EV/EBITDA ¥1.23 ¥1.65 ¥2.08 67
EV/Revenue ¥0.3000 ¥0.4500 ¥0.5900 52
Asset-Based
NCAV (Graham) ¥0.0100 ¥0.0200 ¥0.0200 55
Growth DCF
Growth DCF ¥0.3600 ¥0.5100 ¥0.6900 78
Rev-Margin DCF ¥0.3100 ¥0.4900 ¥0.6900 71
Economic Profit
Residual Income ¥0.7200 ¥0.7100 ¥0.7300 76
ROIC Compounder ¥0.2400 ¥0.2800 ¥0.3100 71
Growth Earnings
Growth-Adj P/E ¥0.6000 ¥0.8600 ¥1.11 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 66/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 29
How much profit the company makes from its sales and capital
Quality Growth 96
Are margins and returns getting better?
Cashflow 54
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 75
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 87
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+58.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Start year 2020 (pandemic). Over 10 years: +1.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.2%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.2% vs −10.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−29% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +52.5% a year for the price.

002693 screens overvalued: fair value 90% below the price. Compare with Merck KGaA →

Compare Hainan Shuangcheng Pharmaceut with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 610 stocks

Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside −89.8% · Bottom 25%
Profitability
Return on equity (12 months) 8.1% · Above median
Return on assets 3.5% · Above median
Net margin (12 months) 22.5% · Top 25%
Operating margin (12 months) 19.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −11.9% · Bottom 25%
Dividend yield (12 months) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.22× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 63.2× · Priciest 25%
P/B 6.99× · Priciest 25%
P/S (12 months) 14.73× · Priciest 25%
Price / free cash flow (fiscal year) 249.7× · Priciest 25%
EV/EBITDA 44.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 23
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)33 · sector 26
HEALTH (low debt)89 · sector 96
DIVIDEND (yield)4 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.11 $113.53 +44% vs 002693
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.00 ¥52.43 +12% vs 002693
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,884.90 ₹1,982.92 +5% vs 002693
Haleon plc HLN $9.07 $8.47 −7% vs 002693
Merck KGaA MRK €146.45 €108.83 −26% vs 002693
Galderma Group GALD CHF 182.85 CHF 112.84 −38% vs 002693
Teva Pharmaceutical Industries Limited TEVA $39.23 $20.74 −47% vs 002693
Takeda Pharmaceutical Company TAK $21.77 $11.26 −48% vs 002693
Sandoz Group SDZ CHF 80.50 CHF 41.06 −49% vs 002693
Divi's Laboratories Limited DIVISLAB ₹11,180.50 ₹1,566.89 −86% vs 002693

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hainan Shuangcheng Pharmaceut: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hainan Shuangcheng Pharmaceut Fair Value". https://www.fairvalue-calculator.com/stock/002693

Frequently asked questions

Is Hainan Shuangcheng Pharmaceut (002693) overvalued or undervalued?
As of Nov 21, 2026, our model estimates a fair value of ¥0.71 versus a price of ¥6.95, about 90% lower (overvalued).
What is the fair value of 002693?
Our model-based fair value for Hainan Shuangcheng Pharmaceut is ¥0.71 (as of Nov 21, 2026), built from audited fundamentals. The current price: ¥6.95.
What is the quality score of 002693?
Hainan Shuangcheng Pharmaceut has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hainan Shuangcheng Pharmaceut (002693)?
We do not set a price target; the yardstick is the fair value of ¥0.71 (as of Nov 21, 2026) from 26 valuation models. Cautious scenario ¥0.44, optimistic scenario ¥1.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Hainan Shuangcheng Pharmaceut stock forecast for 2026?
Our models put fair value at ¥0.71, about 90% lower versus a price of ¥6.95 (overvalued). Cautious scenario ¥0.44, optimistic scenario ¥1.03. The calculation is refreshed regularly with new filings.
What is the revenue of Hainan Shuangcheng Pharmaceut (002693)?
Hainan Shuangcheng Pharmaceut reported trailing-twelve-month revenue of about 300M CNY (latest available figure, as of Nov 21, 2026).
Does Hainan Shuangcheng Pharmaceut pay a dividend?
Hainan Shuangcheng Pharmaceut currently shows a dividend yield of 0.22% relative to its recent price (as of Nov 21, 2026).
How much is the dividend of Hainan Shuangcheng Pharmaceut (002693)?
Hainan Shuangcheng Pharmaceut has a dividend yield of 0.2%.
What growth is priced into Hainan Shuangcheng Pharmaceut (002693)?
For today's price to be fair in a discounted-cash-flow model, Hainan Shuangcheng Pharmaceut would have to grow free cash flow by 55.0 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 0.5 % per year. As of Nov 21, 2026.
What discount rate (WACC) does the fair value of 002693 use?
Our models discount Hainan Shuangcheng Pharmaceut at 10.5 %: a base by market capitalisation (small), damped by beta 0.52, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hainan Shuangcheng Pharmaceut that is +55.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Hainan Shuangcheng Pharmaceut (002693) delivered so far?
Over the past 5 years revenue at Hainan Shuangcheng Pharmaceut grew 0.5 % a year. The price currently implies free-cash-flow growth of +55.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hainan Shuangcheng Pharmaceut (002693) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Hainan Shuangcheng Pharmaceut (+55.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hainan Shuangcheng Pharmaceut (002693)?
The free-cash-flow yield on the price is 0.61 %: that much free cash flow Hainan Shuangcheng Pharmaceut produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hainan Shuangcheng Pharmaceut (002693)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hainan Shuangcheng Pharmaceut it is ¥0.71 per share (as of Nov 21, 2026), against a price of ¥6.95. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hainan Shuangcheng Pharmaceut stock overvalued or undervalued in 2026?
As of Nov 21, 2026, 002693 trades above its calculated fair value: price ¥6.95, fair value ¥0.71, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002693?
No. The price is what the market pays today (¥6.95); the fair value is what the company's own numbers justify (¥0.71). For Hainan Shuangcheng Pharmaceut the two are ¥6.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hainan Shuangcheng Pharmaceut worth?
The market values Hainan Shuangcheng Pharmaceut at about 2.9B CNY (market capitalisation, as of Nov 21, 2026). Per share that is ¥6.95; our models calculate a fair value of ¥0.71 per share.
What do the bullish and bearish scenarios say about 002693?
Our models span a range for Hainan Shuangcheng Pharmaceut: cautious scenario ¥0.44, base ¥0.71, optimistic ¥1.03 per share (as of Nov 21, 2026, price ¥6.95). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002693?
Hainan Shuangcheng Pharmaceut trades at a price-to-earnings ratio of 63.2 (as of Nov 21, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥0.71 is built from several models across several years. Other multiples: P/B 7.0, P/S 14.7, EV/EBITDA 44.2.
How solid is the balance sheet of Hainan Shuangcheng Pharmaceut (002693)?
Balance-sheet figures for Hainan Shuangcheng Pharmaceut (as of Nov 21, 2026): return on equity 8.1%, debt of 0.22 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 002693 from its 52-week high?
Hainan Shuangcheng Pharmaceut trades at ¥6.95, about 40% below its 52-week high of ¥11.61 and 7% above the low of ¥6.52 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.71 is for.
Which stocks are comparable to Hainan Shuangcheng Pharmaceut?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hainan Shuangcheng Pharmaceut stock attractive at the current price?
The data as of Nov 21, 2026: price ¥6.95, calculated fair value ¥0.71 (−90%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002693 calculated?
We run Hainan Shuangcheng Pharmaceut through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥0.71 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 9.6% above its aggregate fair value. Hainan Shuangcheng Pharmaceut itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hainan Shuangcheng Pharmaceut (002693)?
The closing price on Nov 20, 2026 was ¥6.95. Our model-based fair value is ¥0.71, about 90% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hainan Shuangcheng Pharmaceut right now?
The price sits above even our optimistic bull case (¥1.03). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥0.44 to ¥1.03) leaves room in how you read the outcome.

Key figures of Hainan Shuangcheng Pharmaceut

How large is the market capitalisation of Hainan Shuangcheng Pharmaceut (002693)?
The market capitalisation of Hainan Shuangcheng Pharmaceut is 2.9B CNY (≈ $432M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hainan Shuangcheng Pharmaceut (002693)?
The price-to-sales ratio of Hainan Shuangcheng Pharmaceut is 8.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hainan Shuangcheng Pharmaceut (002693)?
Earnings per share at Hainan Shuangcheng Pharmaceut are ¥0.11 (price ÷ EPS = P/E 63.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hainan Shuangcheng Pharmaceut (002693)?
The dividend yield of Hainan Shuangcheng Pharmaceut is 0.2% (payout 14.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hainan Shuangcheng Pharmaceut (002693)?
The net margin of Hainan Shuangcheng Pharmaceut is 14.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hainan Shuangcheng Pharmaceut (002693)?
The return on equity (ROE) of Hainan Shuangcheng Pharmaceut is 8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hainan Shuangcheng Pharmaceut (002693)?
On an EBIT basis the return on assets of Hainan Shuangcheng Pharmaceut is −5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hainan Shuangcheng Pharmaceut (002693)?
The operating margin of Hainan Shuangcheng Pharmaceut is 19.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hainan Shuangcheng Pharmaceut (002693)?
Revenue at Hainan Shuangcheng Pharmaceut is down 11.9% versus a year earlier (3y avg +0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hainan Shuangcheng Pharmaceut (002693)?
Earnings per share at Hainan Shuangcheng Pharmaceut are down 45.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hainan Shuangcheng Pharmaceut (002693) carry?
The net debt of Hainan Shuangcheng Pharmaceut is 29.9M CNY (fiscal year 2025, ≈ 1.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hainan Shuangcheng Pharmaceut in the live analysis

One click puts Hainan Shuangcheng Pharmaceut on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.